

TITAX AMI Trial

Prospective, multi-center, randomized trial

TiTAN2™ vs. TAXUS Liberté™

TRIAL DESIGN

■ 425 enrolled patients

■ Follow-up : 100%

■ Endpoints :
MACE to 12, 18 and 24 months

2 YEARS

INDICATION: ACUTE CORONARY SYNDROMES

	Ti TAN 2™	TAXUS Liberté™	P value
NSTEMI	61%	54%	NS
STEMI	39%	46%	NS


CHARACTERISTICS

	Ti TAN 2™	TAXUS Liberté™	P value
Diabetes (%)	22.4	15.6	0.08
Previous PCI (%)	10.3	4.7	0.04
RVD (mm)	3.16 ± 0.45	3.11 ± 0.50	0.35
Lesion length (mm)	13.6 ± 5.6	13.2 ± 6.4	0.47

TITAX AMI Trial


Ti TAN2™ vs. TAXUS Liberté™

24-MONTH RESULTS



The Ti TAN2™ B.A.S.* Efficacy and Safety are significantly superior with a MACE reduction of 49% and a Cardiac Death reduction of 81%

FOLLOW-UP AVAILABLE UP TO 24 MONTHS



At 2-year follow-up, the Ti TAN2™ B.A.S.* continues to provide clinical benefits and sustained efficacy compared to the control Taxus™ group

*B.A.S.: Bio Active Stent



HEXACATH

4, Passage Saint Antoine
92508 Rueil-Malmaison Cedex
Tel : + 33 (0)1 41 39 01 92
Fax: + 33 (0)1 41 39 01 93



Late Breaking Coronary Trials

Speaker: P. Karjalainen